Impact BioMedical Inc.
IBO
$0.78
$0.3268.47%
AMEX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -61.11% | 157.14% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -61.11% | 157.14% | |||
| Cost of Revenue | 42,100.00% | -90.91% | |||
| Gross Profit | -2,541.18% | 525.00% | |||
| SG&A Expenses | -46.71% | -23.67% | |||
| Depreciation & Amortization | -0.69% | 0.00% | |||
| Other Operating Expenses | -33.94% | -0.91% | |||
| Total Operating Expenses | 20.60% | -16.72% | |||
| Operating Income | -22.15% | 17.78% | |||
| Income Before Tax | 280.00% | 89.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 454.92% | 89.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 100.00% | -16.67% | |||
| Net Income | 456.80% | 89.75% | |||
| EBIT | -22.15% | 17.78% | |||
| EBITDA | -847.83% | 92.01% | |||
| EPS Basic | 148.42% | 89.76% | |||
| Normalized Basic EPS | 124.87% | 89.78% | |||
| EPS Diluted | 147.43% | 89.78% | |||
| Normalized Diluted EPS | 124.87% | 89.78% | |||
| Average Basic Shares Outstanding | 636.68% | 0.00% | |||
| Average Diluted Shares Outstanding | 636.68% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||